Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Portola Pharma (PTLA)

Portola Pharma (PTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 536,410
  • Shares Outstanding, K 78,080
  • Annual Sales, $ 116,640 K
  • Annual Income, $ -290,660 K
  • 60-Month Beta 1.98
  • Price/Sales 4.73
  • Price/Cash Flow N/A
  • Price/Book 4.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.70
  • Number of Estimates 3
  • High Estimate -0.63
  • Low Estimate -0.78
  • Prior Year -1.02
  • Growth Rate Est. (year over year) +31.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.31 +29.38%
on 03/17/20
10.40 -33.94%
on 03/02/20
-3.30 (-32.45%)
since 02/27/20
3-Month
5.31 +29.38%
on 03/17/20
25.09 -72.62%
on 12/30/19
-18.19 (-72.59%)
since 12/27/19
52-Week
5.31 +29.38%
on 03/17/20
37.95 -81.90%
on 04/05/19
-25.95 (-79.07%)
since 03/27/19

Most Recent Stories

More News
Portola Pharmace Has Returned 72.3% Since SmarTrend Recommendation (PTLA)

SmarTrend identified a Downtrend for Portola Pharmace (NASDAQ:PTLA) on December 17th, 2019 at $25.66. In approximately 3 months, Portola Pharmace has returned 72.29% as of today's recent price of $7.11....

PTLA : 6.87 (-2.69%)
Portola Pharmaceuticals Announces Proactive Steps Supporting Public Health Efforts to Combat Coronavirus (COVID-19)

Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced proactive steps the Company is taking in support of public heath efforts to prevent furtherspread of coronavirus (or COVID-19) around the...

PTLA : 6.87 (-2.69%)
Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new data reinforcing the value of Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only FDA-approved reversal...

PTLA : 6.87 (-2.69%)
PORTOLA 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Portola Pharmaceuticals, Inc. - PTLA

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until March 16, 2020 to file lead plaintiff applications...

PTLA : 6.87 (-2.69%)
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Portola Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Northern District of...

PTLA : 6.87 (-2.69%)
PORTOLA 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Portola Pharmaceuticals, Inc. - PTLA

Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until March 16, 2020 to file lead plaintiff applications...

PTLA : 6.87 (-2.69%)
PTLA Final Deadline Monday: Rosen, a Globally Recognized Firm, Reminds Portola Pharmaceuticals, Inc. Investors of Important March 16th Deadline in Securities Class Action - PTLA

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) between January 8, 2019 and February 26, 2020, inclusive (the "Class...

PTLA : 6.87 (-2.69%)
PTLA INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Portola Pharmaceuticals Inc. Investors With Losses Exceeding $100K of Class Action and Lead Deadline: March 16, 2020

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Portola Pharmaceuticals Inc. ("Portola" or the Company") (NASDAQ: PTLA)...

PTLA : 6.87 (-2.69%)
ROSEN, NATIONAL INVESTOR COUNSEL, Reminds Portola Pharmaceuticals, Inc. Investors of Important March 16th Deadline in Securities Class Action - PTLA

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) between May 8, 2019 and January 9, 2020, inclusive (the "Class Period")...

PTLA : 6.87 (-2.69%)
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS ALGN, OPRA, PTLA, QD INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

ALGN : 177.04 (-7.62%)
OPRA : 5.20 (-5.97%)
PTLA : 6.87 (-2.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade PTLA with:

Business Summary

Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.

See More

Key Turning Points

2nd Resistance Point 7.39
1st Resistance Point 7.13
Last Price 6.87
1st Support Level 6.54
2nd Support Level 6.21

See More

52-Week High 37.95
Fibonacci 61.8% 25.48
Fibonacci 50% 21.63
Fibonacci 38.2% 17.78
Last Price 6.87
52-Week Low 5.31

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar